公司資料
GENFIT 股價、新聞與催化劑
- 股票代碼:
- GNFT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- France and listed in the U
股價為何變動
Current closing-price context is not available for GNFT.
公司概覽
Liver-Disease Therapeutics and Diagnostics
GENFIT develops therapies and diagnostic technologies for liver diseases. Its portfolio combines commercial economics from a partnered product with internal programs in cholangiocarcinoma and acute-on-chronic liver failure.
Iqirvo Economics
GENFIT receives milestones and royalties from Ipsen’s commercialization of Iqirvo in primary biliary cholangitis. Ipsen is also leading a Phase 3 study in primary sclerosing cholangitis, extending the molecule into another cholestatic liver disease.
MASH Diagnostics
The company has developed non-invasive diagnostic technology for metabolic dysfunction-associated steatohepatitis. It is commercializing a laboratory-developed test and preparing in vitro diagnostic development to support patient identification as the treatment market expands.
GNS561 in Cholangiocarcinoma
GNS561 is being evaluated in combination therapy for cholangiocarcinoma. Additional Phase 1b results are intended to inform a planned Phase 2 study.
NTZ in ACLF
NTZ is the lead internal program for acute-on-chronic liver failure. GENFIT plans to move the asset into Phase 2 proof-of-concept development in a condition with high short-term mortality and limited treatment options.
未來催化劑
- Additional Phase 1b GNS561 combination data in cholangiocarcinoma expected in mid-2026.
- Initiation of Phase 2 development for GNS561 targeted in the second half of 2026.
- Initiation of a Phase 2 NTZ trial in ACLF expected in the second half of 2026, with data in 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。